(SILO) – Company Press Releases
-
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
-
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
-
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
-
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
-
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
-
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
-
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
-
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
-
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
-
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
-
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
-
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
-
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
-
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
-
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
-
Silo Wellness Announces LOI to Acquire NUGL/Kaya in a Transaction Valued at CAD $43,289,624.60; CSE to Halt Trading Until Shareholder Approval
-
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
-
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
-
Jamaica Based Kaya Group Forges Partnership with Silo Wellness for Psychedelic Wellness Experiences and Retreats; Announces Share Exchange Agreement
-
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
-
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
-
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
-
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
-
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
-
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
-
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
-
Moon Equity Holdings to Sell BitGift Asset to Silo Wellness in Exchange for a Dividend
-
Silo Pharma to Present at Psychedelic Drug Development Conference
-
Silo Pharma to Present at Psychedelic Drug Development Conference
-
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
-
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
-
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
-
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
-
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
-
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
-
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
-
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
-
Silo Pharma Announces Expansion of Intellectual Property Portfolio
-
Silo Pharma Announces Expansion of Intellectual Property Portfolio
-
Silo Pharma Announces Stock Repurchase Program
-
Silo Pharma Announces Stock Repurchase Program
-
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
-
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
-
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
-
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
-
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
-
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
-
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
-
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
Back to SILO Stock Lookup
